View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2021

Medicago and GSK initiate late-stage study of adjuvanted Covid vaccine

Canada’s Medicago has started a late-stage study of its plant-derived Covid-19 vaccine candidate combined with GSK's pandemic adjuvant.

Canada’s Medicago has started a late-stage study of its plant-derived Covid-19 vaccine candidate combined with GSK’s pandemic adjuvant.

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

The move comes a month after the vaccine candidate, in combination with the pandemic adjuvant, secured fast track designation from the US Food and Drug Administration (FDA).

Medicago’s vaccine candidate uses a technology called virus-like-particles (VLPs) to mimic the structure of coronavirus.

In the Phase III trial, the vaccine, composed of recombinant spike (S) glycoprotein, will be co-administered with GSK’s pandemic adjuvant on participants in a two dose regimen 21 days apart.

The event-driven, randomised, observer-blinded, placebo-controlled study will evaluate the efficacy and safety of the adjuvanted formulation compared to placebo.

Medicago seeks to enrol up to 30,000 subjects, initially focusing healthy adults and followed by elderly adults (more than 65 years of age) and those with comorbidities.

The company has already received approval from Canadian and US regulatory authorities to commence the enrolment process.

Separately, Medicago started a feasibility study of a vaccine candidate to address the emerging Covid-19 variants.

Medicago president and CEO Takashi Nagao said: “We are pleased to take the significant step of initiating the Phase III clinical trial at sites around the world.

“This brings us one step closer to delivering an important new Covid-19 vaccine and contributing to the global fight against the pandemic along with our partner GSK.”

GSK Vaccines chief medical officer Thomas Breuer said: “This advance to late stage clinical testing further reinforces our confidence in the adjuvanted vaccine candidate’s potential to make a difference in the continued fight against Covid-19. We look forward to sharing results later this year.”

The Phase II portion of the trial is now nearing completion and the results are expected to be published next month.

In a separate development, Cytocom announced that the FDA had cleared the Investigational New Drug (IND) application for a Phase II clinical trial that seeks to assess the efficacy of CYTO-205 in slowing or halting the progression of SARS-CoV-2.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena